Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy?

Daniel Batlle*, Jan Wysocki, Karla Satchell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

175 Scopus citations

Abstract

A new coronavirus, referred to as SARS-CoV-2, is responsible for the recent outbreak ofsevere respiratory disease. This outbreak first detected in Wuhan, China in December 2019,has spread to other regions of China and to 25 other countries as of January, 2020. It hasbeen known since the 2003 SARS epidemic that the receptor critical for SARS-CoV entryinto host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spikeprotein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. Wethought that it is timely to explain the connection between the SARS-CoV, SARS-CoV-2,ACE2 and the rationale for soluble ACE2 as a potential therapy.

Original languageEnglish (US)
Pages (from-to)543-545
Number of pages3
JournalClinical science
Volume134
Issue number5
DOIs
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Soluble angiotensin-converting enzyme 2: A potential approach for coronavirus infection therapy?'. Together they form a unique fingerprint.

Cite this